Market capitalization | $12.79b |
Enterprise Value | $14.63b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.60 |
P/S ratio (TTM) P/S ratio | 4.90 |
P/B ratio (TTM) P/B ratio | 4.00 |
Revenue growth (TTM) Revenue growth | 13.54% |
Revenue (TTM) Revenue | $2.61b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
24 Analysts have issued a Exact Sciences Corporation forecast:
24 Analysts have issued a Exact Sciences Corporation forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -204 -204 |
67%
67%
|
|
Depreciation and Amortization | 235 235 |
4%
4%
|
|
Stock Compensation | 231 231 |
12%
12%
|
|
Operating Cash Flow | 156 156 |
170%
170%
|
|
Investments | 124 124 |
42%
42%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | 32 32 |
107%
107%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection of colorectal cancer and pre-cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.
Head office | United States |
CEO | Kevin Conroy |
Employees | 6,600 |
Founded | 1995 |
Website | www.exactsciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.